SCHEMBL18790973

SCHEMBL18790973

COCc1ccc(-c2cnnc(N3CCN(CC(=O)O)CC3)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 3/20 0.43
▸ MAP4K1 Q92918 1/20 0.40
▸ HTR6 P50406 1/20 0.40
▸ S1PR1 P21453 1/20 0.39
▸ CYP11B1 P15538 2/20 0.39
▸ PDE5A O76074 1/20 0.35
▸ MAPT P10636 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ USP2 O75604 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ LRRK2 Q5S007 1/20 0.35
▸ SLCO1B1 Q9Y6L6 1/20 0.35
▸ SLC6A7 Q99884 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18790971 0.91 CYP11B2 (0.44) CYP11B2MAP4K1HTR6CYP11B1MAPT
SCHEMBL18790704 0.82 SLC6A9 (0.47) CYP11B2CYP11B1SMN1; SMN2
SCHEMBL18790970 0.80 TGFBR1 (0.42) MAP4K1HTR6CYP3A4KCNH2CYP2C9
SCHEMBL18791106 0.77 CYP11B2 (0.53) CYP11B2CYP11B1MAPTALDH1A1SMN1; SMN2
SCHEMBL18791027 0.76 CYP11B2 (0.48) CYP11B2CYP11B1CYP3A4CYP1A2CYP2C9
SCHEMBL18790697 0.75 CYP11B2 (0.69) CYP11B2CYP11B1MAPTSLC6A7
SCHEMBL18791041 0.74 CYP11B2 (0.45) CYP11B2CYP11B1LMNAGSK3B
SCHEMBL18791026 0.74 GAA (0.53) CYP11B2CYP11B1CYP3A4SCN9ACYP1A2
SCHEMBL25270964 0.72 S1PR1 (0.44) CYP11B2S1PR1MAPTALDH1A1LMNA
SCHEMBL18791093 0.71 CYP11B2 (0.66) CYP11B2CYP11B1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3381904-B1 NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2021-07-28 — — EP disclosed
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-07-21 — — US disclosed
WO-2017069226-A1 NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2017-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound REN, NR3C2, NR5A1 CYP11B2 8/4885MAP4K1 1167/4885HTR6 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback